Drugs / VALANAFUSP ALFA
VALANAFUSP ALFA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02597114 | Nov 2015 → Mar 2018 | mucopolysaccharidosis type 1 | ArmaGen, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02371226 | Jul 2015 → Jan 2017 | mucopolysaccharidosis type 1 | ArmaGen, Inc | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03071341 | Oct 2016 → Feb 2018 | mucopolysaccharidosis type 1 | ArmaGen, Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT03053089 | Oct 2015 → Feb 2018 | mucopolysaccharidosis type 1 | ArmaGen, Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VALANAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297553 ↗ |
| Known as | AGT-181 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02371226 ↗ |
| Known as | HIRMAb-IDUA | “Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein” NCT03071341 ↗1“AGT-181 (HIRMAb-IDUA)” NCT02371226 ↗ |
| Known as | valanafusp alpha | “To enable BBB transport, IDUA was re-engineered as an IgG-IDUA fusion protein, valanafusp alpha, where the IgG domain targets the BBB human insulin receptor to enable transport...” PMID 29976218 ↗ Jul 2018 |
| Modality | Protein / enzyme biologic | “AGT-181 is a fusion protein containing alpha-L-Iduronidase” NCT02371226 ↗ |
| Route | Intravenous | “intravenous infusion over 3-4 hours” NCT02371226 ↗ |